Literature DB >> 20432469

Expression profiling of ETS and MMP factors in VEGF-activated endothelial cells: role of MMP-10 in VEGF-induced angiogenesis.

Sun-Hee Heo1, Young-Jin Choi, Hyun-Mo Ryoo, Je-Yoel Cho.   

Abstract

In the process of angiogenesis, working of many transcription factors at the proper time is important to activate angiogenesis-related genes such as cytokine, matrix protease and adhesion molecules. In this study, we searched for Ets transcription factors and matrix metalloproteinases (MMPs) that respond to VEGF in endothelial cells. We first analyzed the expression of 27 human Ets factors and 15 human MMPs in VEGF-treated human umbilical vein endothelial cells (HUVEC) using quantitative RT-PCR. The most abundant Ets factors in HUVEC were ETS-1, Fli-1, ERP/NET/ELK3, and ERG. MMP-1, -2, -10, -11, -14, -15, and -16 were also detected in HUVEC. We also found that ETV-1, Fli-1, ERG, MMP-1, -3, -7, -8, -9, -10, -13, and -19 expression is up-regulated more than 1.5-fold in HUVEC after 2 h of VEGF treatment. In addition, the expression of MMP-10 induced by VEGF remained twofold higher for 24 h compared to non-treated control. The elevation of MMP10 mRNA and protein levels was confirmed to be both time- and dosage-dependent. In addition, MMP-10 transcription was mediated by Ets-1 but not ERP/NET/ELK3. The inhibition of PI3K and MAPK inhibited VEGF-induced MMP-10 expression. Furthermore, transfection of MMP-10 siRNA inhibited VEGF-induced migration and tube formation in HUVEC, and it also inhibited vessel formation in matrigel plugs in vivo. In conclusion, our study demonstrated induction of MMP-10 by VEGF in HUVEC and supports an angiogenic role for MMP-10 in response to VEGF stimulation in vitro and in vivo. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20432469     DOI: 10.1002/jcp.22175

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  24 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 3.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 4.  Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia.

Authors:  Juanjuan Chen; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-22       Impact factor: 3.622

5.  The Activation of Human Dermal Microvascular Cells by Poly(I:C), Lipopolysaccharide, Imiquimod, and ODN2395 Is Mediated by the Fli1/FOXO3A Pathway.

Authors:  Lukasz Stawski; Grace Marden; Maria Trojanowska
Journal:  J Immunol       Date:  2017-11-15       Impact factor: 5.422

Review 6.  Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.

Authors:  Biagio Ricciuti; Jennifer Foglietta; Rita Chiari; Amirhossein Sahebkar; Maciej Banach; Vanessa Bianconi; Matteo Pirro
Journal:  Med Oncol       Date:  2017-12-04       Impact factor: 3.064

7.  ETS factors regulate Vegf-dependent arterial specification.

Authors:  Joshua D Wythe; Lan T H Dang; W Patrick Devine; Emilie Boudreau; Stanley T Artap; Daniel He; William Schachterle; Didier Y R Stainier; Peter Oettgen; Brian L Black; Benoit G Bruneau; Jason E Fish
Journal:  Dev Cell       Date:  2013-07-03       Impact factor: 12.270

8.  Mass spectrometry identification of potential mediators of progestin-only contraceptive-induced abnormal uterine bleeding in human endometrial stromal cells.

Authors:  John P Shapiro; Murat Basar; Umit A Kayisli; Ozlem Guzeloglu-Kayisli; S Joseph Huang; Adrian A Suarez; Hatice Gulcin Ozer; Frederick Schatz; Charles J Lockwood
Journal:  Contraception       Date:  2014-11-21       Impact factor: 3.375

Review 9.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

10.  RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells.

Authors:  Sadaaki Yamazoe; Hiroaki Tanaka; Tetsuji Sawada; Ryosuke Amano; Nobuya Yamada; Masaichi Ohira; Kosei Hirakawa
Journal:  J Exp Clin Cancer Res       Date:  2010-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.